💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for BRAI

No earnings history available for this symbol.

📰 Related News & Research

• Adaptin Bio, Inc. 2025 Annual Report: Pioneering Brain Cancer Therapies and Novel Drug Delivery Technologies
  April 2, 2026
  

  Adaptin Bio, Inc. 2025 Annual Report Detailed Investor Artic...

• NeOnc Technologies: Innovative Drug Delivery Platforms and Pipeline for Brain Cancer and CNS Disorders
  March 31, 2026
  

  NeOnc Technologies Holdings, Inc. (NTHI) 2025 Annual Report ...

• Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program
  March 26, 2026
  

  Acumen Pharmaceuticals Reports 2025 Full-Year Financial Resu...

• InMed Pharmaceuticals Reports Positive INM-901 Data in Human Brain Organoid Models for Alzheimer’s Disease Program 12
  March 23, 2026
  

  InMed Pharmaceuticals Reports Positive Preclinical Data for ...

• Hyperfine Swoop® Portable AI-Powered MRI System: Revolutionizing Accessible Brain Imaging and Expanding Global Healthcare Markets 44
  March 19, 2026
  

  Hyperfine, Inc. 2025 Annual Report Highlights Hyperfine,...

• ONP-002: Development-Stage Biopharmaceutical Therapy for Mild Traumatic Brain Injury (Concussion) – Clinical Pipeline, Regulatory Pathways, and Commercialization Strategy
  March 17, 2026
  

  Oragenics Inc. 2025 Annual Report – Investor Highlights and ...

• Acumen Pharmaceuticals Raises $35.75 Million to Advance Enhanced Brain Delivery Alzheimer’s Therapy with Strong Preclinical Results 1
  March 16, 2026
  

  Acumen Pharmaceuticals Announces \$35.75 Million Private Pla...

• Brainhole Technology Announces Discloseable Transactions: Acquisition of AOI and AXT Shares, Disposal of Nebius Shares (March 2026)
  March 15, 2026
  

  Brainhole Technology Limited: Discloseable Transactions in L...

• CervoMed Inc. Annual Report 2025: Strategy, Key Terms, and Forward-Looking Statements for Age-Related Brain Disorders
  March 13, 2026
  

  CervoMed Inc. 2025 Annual Report: Key Insights for Investors...

• Oragenics Receives Australian HREC Approval to Begin Phase IIa Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury
  March 12, 2026
  

  Oragenics Receives HREC Approval for Phase IIa Clinical Tria...

🔍 View more Reports